Sonnet BioTherapeutics (SONN) Competitors $1.12 -0.09 (-7.08%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. SNYR, COCP, CING, LPCN, LPTX, UBX, UPXI, MBRX, NRSN, and INABShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Synergy CHC Corp. (Uplisting) (SNYR), Cocrystal Pharma (COCP), Cingulate (CING), Lipocine (LPCN), Leap Therapeutics (LPTX), Unity Biotechnology (UBX), Upexi (UPXI), Moleculin Biotech (MBRX), NeuroSense Therapeutics (NRSN), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Synergy CHC Corp. (Uplisting) Cocrystal Pharma Cingulate Lipocine Leap Therapeutics Unity Biotechnology Upexi Moleculin Biotech NeuroSense Therapeutics IN8bio Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings. Do institutionals and insiders believe in SNYR or SONN? 9.4% of Sonnet BioTherapeutics shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend SNYR or SONN? Synergy CHC Corp. (Uplisting) presently has a consensus target price of $10.00, indicating a potential upside of 410.20%. Sonnet BioTherapeutics has a consensus target price of $20.00, indicating a potential upside of 1,701.80%. Given Sonnet BioTherapeutics' higher probable upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than Synergy CHC Corp. (Uplisting).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SNYR or SONN? In the previous week, Synergy CHC Corp. (Uplisting) had 45 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 45 mentions for Synergy CHC Corp. (Uplisting) and 0 mentions for Sonnet BioTherapeutics. Synergy CHC Corp. (Uplisting)'s average media sentiment score of 0.00 equaled Sonnet BioTherapeutics'average media sentiment score. Company Overall Sentiment Synergy CHC Corp. (Uplisting) Neutral Sonnet BioTherapeutics Neutral Which has stronger earnings & valuation, SNYR or SONN? Synergy CHC Corp. (Uplisting) has higher revenue and earnings than Sonnet BioTherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC Corp. (Uplisting)$34.83M0.49N/AN/AN/ASonnet BioTherapeutics$1M3.51-$7.44MN/AN/A Is SNYR or SONN more profitable? Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC Corp. (Uplisting)N/A N/A N/A Sonnet BioTherapeutics N/A -408.93%-174.13% Does the MarketBeat Community favor SNYR or SONN? Sonnet BioTherapeutics received 20 more outperform votes than Synergy CHC Corp. (Uplisting) when rated by MarketBeat users. Likewise, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 66.67% of users gave Synergy CHC Corp. (Uplisting) an outperform vote. CompanyUnderperformOutperformSynergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% Sonnet BioTherapeuticsOutperform Votes2284.62% Underperform Votes415.38% SummarySynergy CHC Corp. (Uplisting) and Sonnet BioTherapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.51M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.1226.8519.75Price / Sales3.51256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.846.436.764.50Net Income-$7.44M$144.21M$3.23B$248.32M7 Day Performance-9.76%2.25%1.71%0.48%1 Month Performance-13.62%4.39%11.16%13.08%1 Year Performance-36.21%-2.71%17.17%7.36% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.063 of 5 stars$1.12-7.1%$20.00+1,693.7%-27.3%$3.53M$1M0.0010SNYRSynergy CHC Corp. (Uplisting)2.573 of 5 stars$1.83+3.4%$10.00+446.4%N/A$16.02M$34.83M0.0040Trending NewsEarnings ReportAnalyst RevisionGap DownCOCPCocrystal Pharma3.1462 of 5 stars$1.57+3.0%$7.00+347.3%-24.7%$15.92MN/A-0.8510Earnings ReportAnalyst RevisionCINGCingulate2.3114 of 5 stars$3.98-0.7%$30.67+670.5%+301.2%$15.69MN/A-0.4720News CoverageAnalyst ForecastAnalyst RevisionGap UpLPCNLipocine1.542 of 5 stars$2.92-11.0%$10.00+242.5%-44.6%$15.62M$11.20M-3.8410News CoverageGap UpHigh Trading VolumeLPTXLeap Therapeutics2.4371 of 5 stars$0.38+12.0%$4.92+1,210.8%-85.6%$15.54MN/A-0.1940Positive NewsGap UpUBXUnity Biotechnology3.654 of 5 stars$0.90-1.5%$5.33+492.6%-49.5%$15.49M$240,000.00-0.6960Gap UpUPXIUpexi0.6451 of 5 stars$10.64+7.4%N/A+36.0%$15.17M$18.63M0.00130Earnings ReportHigh Trading VolumeMBRXMoleculin Biotech1.9708 of 5 stars$1.08+2.9%$6.00+455.6%-80.4%$15.12MN/A0.0020Gap UpNRSNNeuroSense Therapeutics2.4467 of 5 stars$1.10+5.4%N/A+19.0%$15.03MN/A-1.7210Gap UpINABIN8bio3.2095 of 5 stars$0.16+3.6%$6.00+3,581.0%-87.5%$14.80MN/A-0.2220Gap Up Related Companies and Tools Related Companies Synergy CHC Corp. (Uplisting) Competitors Cocrystal Pharma Competitors Cingulate Competitors Lipocine Competitors Leap Therapeutics Competitors Unity Biotechnology Competitors Upexi Competitors Moleculin Biotech Competitors NeuroSense Therapeutics Competitors IN8bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SONN Stock Free SONN Stock Alerts